Skip to content


Registration and Welcome Coffee


Chair’s Opening Remarks



Alexey Lugovskoy
Chief Development Officer
Morphic Therapeutics

Spotlight on Fibrotic Disease Areas


Case Study: Novel Compounds to Target Alstrom

  • Develop a drug that works through binding activation and inhibition
    of receptors found in macrophages and immune cells
  • Target the initial inflammatory process to prevent the progression of fibrotic disease

Jean-Francois Thibodeau
Research Scientist
Prometic Biosciences


Fireside Chat: Advancements in Cardiovascular Fibrosis

  • Discover new therapeutic targets outside of diabetes and blood-pressure which contribute to cardiovascular disease
  • Detect myocardial fibrosis with collagen and IL11 biomarkers
  • Selective small molecule inhibitors within cardiac fibrosis


Sten R. Sorensen
Chief Executive Officer
Cereno Scientific


Bertram Pitt
Professor of Medicine
University of
Michigan School of


Panel: Advancements in Metabolic Fibrosis

  • Combination therapies for NASH and Chronic Kidney Disease
  • The relationship between diabetes and CKD – can common therapies be effectively used to treat both conditions?
  • Tissue targeting in CKD – increasing efficacy, reducing toxicity
  • Novel molecular targets including Galectin-3 inhibitors and HSP47


Matthew Breyer
Distinguished Scientist CVM


Min Lu
Morphic Therapeutics
Head of Fibrosis

Tim Johnson
Director Immunology
Therapeutic Area

Lisa Hazelwood
Principal Scientist Liver Disease and
Fibrosis Discovery

Resat Cinar
Staff Scientist
National Institute
on Alcohol Abuse and


Panel: Advancements in Pulmonary Fibrosis

  • The relationship between Pulmonary Arterial Hypertension and IPF – common mechanisms to target and combination therapies
  • The transference of inhalant technology from COPD to IPF
  • Small molecule therapies that target novel mechanisms


Scott Macdonnell
Senior Staff Scientist


Rozsa Schlenker - Herceg
Executive Director Clinical
Research, Medical
Affairs and Respiratory
Boehringer - Ingelheim

Weilin Xie
Senior Principal Scientist
Celgene Corporation

Rick Keenan
Chief Scientific Officer

Moustapha El-Amine
Director Global Search
and Evaluate


Morning Networking Break

Spotlight on the Relationship between Fibrosis and Cancer


Case Study: Novel Inhibitors of TGF Beta for Fibrotic Cancer

  • Tackle the barrier created by fibroblasts in the tumour microenvironment which prevents immune cells from targeting cancerous cells
  • Understand the role of TGF Beta within fibrotic cancers and create a novel inhibitor of TGF Beta Ligands
  • Consider the role of stromal components and the secretion of cytokines within cancer fibroblast to find a combined immune checkpoint and TGF Beta inhibitors treatment

Gilles Tremblay
Director Preclinical


Panel: You Can’t Teach an Old Pathway New Tricks; the Case for and Against TGF Beta as a Primary Target for Fibrosis and Fibrotic Cancers

  • Can inhibiting TGF Beta alone stop the progression of fibrosis?
  • Does the reduction of TGF Beta in animal models result in strong histological end points at clinical trial?
  • Is there a common TGF Beta pathway to target which will attack fibrotic cancers?


Gilles Tremblay
Director Preclinical


Ravi Kumar
Senior Vice President
and Chief Scientific
Acceleron Pharma

Zoe Johnson
Chief Scientific Officer


Clinical Sessions: Overcoming Failures


Tactics to move a clinical trial to phase III with minimal risk of failure

  • Understand the main causes of AFDD clinical trial failures and discover solutions that prevent future breakdowns
  • Clinical trial design which is failure-proof
  • Learn to pre-empt and adapt in the face of problems to ensure success



A Blueprint for Success: J&J’s CREDENCE Clinical Trial

  • Patient recruitment: a global multidisciplinary effort required perseverance
  • Adjudication: a concerted cross-functional effort required diligence and determination
  • Patient retention: a top priority from Day 1 left no stone unturned

Robert Edwards
Director and CVM
Clinical Project Specialist


Q&A Panel: Overcoming Clinical Trial Failures



Lunch Break



End of Conference Wrap Up Roundtables

10 tables, 10 problems, 10 solutions. Ready, set, resolve!

  • Select a pathway outside of TGF Beta to target in the treatment of fibrosis – define the drug development plan for this pathway
  • Inhibitors vs inducers: create a plan to develop either an inhibiting or inducing anti-fibrotic treatment. Explain why you selected the inhibitor/ inducer.
  • Design a novel biomarker and explain its application to both the preclinical and clinical stage
  • Define a common mechanism to target in order to create an anti-fibrotic drug which will treat all fibrotic disease areas
  • Design a preclinical plan with animal models that will effectively translate to the clinic
  • Design a preclinical plan with only in vitro models
  • Incorporate the use of technology into the development of an anti-fibrotic drug
  • Develop a treatment for a patient with fibrotic cancer
  • Translate J&J’s CREDENCE trial into a clinical trial design for an anti-fibrotic treatment
  • Design a patient recruitment programme for an anti-fibrotic clinical trial

Look to the Future: Academic Showcase


Ocular Fibrosis: See Common Mechanisms in a New Light

  • The non-canonical signalling pathway indicative of ocular fibrosis which is also found in IPF and renal
  • Targeting the transformation to myofibroblasts, from epithelial to mesenchymal cells
  • Learnings from ocular fibrosis mechanisms that share commonalities with other fibrotic conditions and discovery of shared biomarkers

Aftab Taiyab
Research Scientist
McMaster University


The Gut as a Target for Anti-Fibrotic Therapy in NASH

  • Using the gut for systemic immune modulation without immune suppression
  • Generating an immune signal in the gut for re-directing the immune system in an anti-inflammatory way
  • Targeting the gut microbiome for alleviation of fibrosis

Yaron Ilan
Director Department of Medicine
Hebrew University
Hadassah Medical Center


Panel: Spotlight on Scleroderma

  • In vitro skin based assays and how they can be applied to other conditions
  • Genetic skin models including rare disease RDEB
  • Blood test biomarkers indicative of scleroderma

Shervin Assassi
Professor of Medicine and
Co-Director of the UTHealth
Scleroderma Program
University of Texas Health
Science Center at Houston

Robert Lafyatis
Adjunct Professor Medicine
Boston University

Anie Philip
Professor Department of Surgery
Research Institute of the
McGill University Health


Chair’s Closing Remarks

Alexey Lugovskoy
Chief Development Officer
Morphic Therapeutics


Networking Coffee to Stay or Go